Login to Your Account



With SPA Agreement, Xenova Plans Two TransMID Phase IIIs

By Kim Coghill


Wednesday, May 12, 2004
Xenova Group plc immediately expects to commence the first of two planned Phase III trials for TransMID, a candidate for brain cancer. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription